Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset
在未经治疗的EGFR突变转移性非小细胞肺癌患者中,雷莫芦单抗联合厄洛替尼与安慰剂联合厄洛替尼的最终生存结果:RELAY日本亚组
期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2025.100819
Nishio, Makoto; Seto, Takashi; Reck, Martin; Garon, Edward B; Nishio, Kazuto; Kasahara, Kazuo; Nishino, Kazumi; Satouchi, Miyako; Yoh, Kiyotaka; Hayashi, Hidetoshi; Sakai, Kazuko; Enatsu, Sotaro; Frimodt-Møller, Bente; Matsui, Tomoko; Varughese, Sunoj Chacko; Carlsen, Michelle; Visseren-Grul, Carla; Nakagawa, Kazuhiko